Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO and president, Emil D. Kakkis, M.D., Ph.D., will deliver a presentation on Monday, January 13, 2025, at 10:30 AM PT.

The presentation will be accessible via live webcast and can be viewed through the company's investor relations website at https://ir.ultragenyx.com/events-presentations. A replay option will remain available for 30 days following the event. Ultragenyx specializes in developing and commercializing novel therapies for serious rare and ultrarare genetic diseases.

NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 AM PT.

The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the webcast will be available for 30 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com

FAQ

When is Ultragenyx (RARE) presenting at the 2025 J.P. Morgan Healthcare Conference?

Ultragenyx (RARE) will present at the conference on Monday, January 13, 2025, at 10:30 AM PT.

How long will the RARE presentation webcast be available for replay?

The webcast replay will be available for 30 days following the presentation.

Where can investors watch Ultragenyx's J.P. Morgan Healthcare Conference presentation?

Investors can access the presentation through Ultragenyx's investor relations website at https://ir.ultragenyx.com/events-presentations.

What is the focus of Ultragenyx's (RARE) business presentation at JPM 2025?

The presentation will likely focus on their development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, which is the company's primary business focus.